Oncotelic Therapeutics Achieves Milestone with OT-101 Phase 1 Trial
Oncotelic Therapeutics, Inc (OTCQB:OTLC), based in Agoura Hills, California, announced a breakthrough in their research with the successful completion of a Phase 1 clinical trial. This trial evaluated OT-101 in synergy with IL-2, targeting advanced solid tumors. This promising development is paving the way for more in-depth studies that explore the combination of OT-101, an innovative antisense therapeutic specifically targeting Transforming Growth Factor Beta 2 (TGF?2), with checkpoint inhibitors and IL-2.
Key Presentation at SWCR 2025 Conference
The announcement was made in conjunction with a significant presentation by Dr. Vuong Trieu, the Chairman & CEO of Oncotelic, at the 5th Symposium on World Cancer Research (SWCR) 2025. Dr. Trieu's talk, titled "Transforming Growth Factor Beta 2 in Aging, Cancer, Lupus, and Immuno-Oncology: A Convergence of Disease Pathways and Therapeutic Potential," focused on TGF?2's pivotal function in immune suppression across various diseases and the ongoing development of OT-101 in treating cancers such as pancreatic cancer through the Phase 3 STOP-PC study, as well as gliomas.
Completed Phase 1 Trial: OT-101 and IL-2
The Phase 1 trial, which can be referenced under ClinicalTrials.gov ID: NCT04862767, primarily assessed the safety and tolerability of OT-101 when combined with recombinant IL-2 in patients suffering from advanced solid tumors. The findings revealed a promising safety profile, indicating that the combination is tolerable within the planned dosing schedule without any unexpected safety concerns.
Given the positive safety data, Oncotelic plans to move forward with additional clinical studies on OT-101 combined with IL-2, further probing potential synergies with checkpoint inhibitors such as PD-1 blockers.
Highlights from the Recent Presentation
During the Kyoto 2025 presentation, several key insights emerged:
- TGF?2's Fundamental Role in Cancer: Dr. Trieu highlighted that TGF?2 plays a crucial role in fostering immunosuppression, thereby facilitating tumor advancement by fostering a tumor-supportive macrophage environment and stifling anti-tumor immunity.
- Clinical Advancements with OT-101: OT-101 is currently advancing in clinical stages, demonstrating notable activity in pancreatic ductal adenocarcinoma (PDAC) within Phase 3 trials, combined with mFOLFIRINOX. Additionally, significant activity has been noted in gliomas, correlating high levels of intratumoral TGF?2 with poor prognostic outcomes.
- Future Research Focus: Following the successful completion of the Phase 1 trial, Oncotelic is gearing up for further combination trials aimed at enhancing the efficacy of OT-101 and IL-2 paired with checkpoint inhibitors targeting various solid tumors, including lung cancer, melanoma, and colorectal cancer.
Dr. Vuong Trieu expressed enthusiasm about the results: “The completion of our Phase 1 study with OT-101 and IL-2 represents an important step toward developing future immunotherapeutic combinations. Our results underscore the potential of OT-101 in amplifying the immune response against cancer, and we look forward to exploring these interactions with checkpoint inhibitors and IL-2 to expand treatment options for challenging cancers.”
Engaging the Public with Innovative Technology
The presentation, alongside a chatbot powered by PDAOAI, is accessible via the newly introduced PDAOAI public Discord. This platform affords members of the public the opportunity to review the presentation and utilize the chatbot for inquiries related to the topics discussed. This initiative aims to democratize access to cutting-edge AI technology in the field of biotech.
Scott Myers, Product Manager, remarked on the excitement surrounding PDAOAI's public launch, observing, “This presentation is just the start of integrating our AI innovations with the public, opening up access beyond our team.”
About Oncotelic Therapeutics
Oncotelic, formerly known as Mateon Therapeutics, has been a pioneer in oncology treatment since its inception in 1988. The company focuses on enhancing survival rates for cancer patients, particularly in rare pediatric cancer scenarios. Their pipeline includes promising treatments like OT-101 for patients with Diffuse Intrinsic Pontine Glioma (DIPG) through its joint venture with GMP Biotechnology Limited, and they are also working on advances in melanoma and Acute Myeloid Leukemia (AML).
With the acquisition of PointR Data Inc. in November 2019, Oncotelic is determined to leverage artificial intelligence to innovate in drug development. The recent acquisition of AL-101 aims to address several health concerns, from Parkinson's Disease to reproductive health issues, recognizing the significant patient need for viable treatments.
Frequently Asked Questions
What is OT-101?
OT-101 is an antisense therapeutic that targets TGF?2, a protein associated with immune suppression in tumors.
What were the results of the Phase 1 trial?
The Phase 1 trial successfully demonstrated the safety and tolerability of the OT-101 and IL-2 combination, with no unexpected safety issues reported.
What are the future plans for OT-101?
Oncotelic plans to advance OT-101 into additional clinical trials, exploring combinations with checkpoint inhibitors and IL-2 for solid tumors.
How can I access the recent presentation?
The presentation is available on the PDAOAI public Discord server, where viewers can ask questions via the chatbot.
What is Oncotelic's focus as a company?
Oncotelic focuses on developing advanced therapies for cancer treatment, with an emphasis on hard-to-treat cancers and leveraging AI technology for drug development.
